By Suherman Candra Maholtra 
The medical community has long recognized that severe respiratory viruses such as COVID-19 and influenza can cause acute, life-threatening damage to the lungs. However, groundbreaking new research from UVA Health’s Beirne B. Carter Center for Immunology Research and the UVA Comprehensive Cancer Center reveals that the impact of these infections may extend far beyond the initial recovery period. The study suggests that severe viral infections can fundamentally alter the pulmonary environment, creating a "pro-tumor" landscape that facilitates the development and rapid progression of lung cancer months or even years later. Perhaps most significantly, the researchers found that vaccination acts as a critical shield, preventing the long-term immune system disruptions that lead to this increased cancer risk.
Led by Jie Sun, PhD, a prominent scientist at the UVA School of Medicine, the research team identified a direct link between the severity of a respiratory infection and the subsequent likelihood of developing lung malignancies. The findings, published in the prestigious scientific journal Cell, have immediate implications for clinical practice, suggesting that patients who have survived severe bouts of COVID-19, influenza, or viral pneumonia may require enhanced long-term monitoring similar to individuals with a history of heavy smoking.
The Biological Mechanism: How Viruses Reshape the Lung Environment
To understand why a viral infection might trigger cancer years later, Dr. Sun and his colleagues conducted a series of sophisticated experiments using both laboratory mouse models and extensive human patient data. The team focused on the behavior of immune cells within the lung tissue following a severe inflammatory event.
Under normal circumstances, immune cells known as neutrophils and macrophages act as the body’s primary defense mechanism, identifying and destroying pathogens. However, the study revealed that a severe infection can "reprogram" these cells. In the wake of a traumatic respiratory illness, some neutrophils began to behave abnormally, contributing to a state of persistent, low-grade inflammation. Rather than returning to a resting state after the virus was cleared, these cells created an environment that supported, rather than inhibited, tumor growth.
This "pro-tumor" environment is characterized by significant changes in the epithelial cells—the cells that line the lungs—and the alveoli, the tiny air sacs responsible for oxygen exchange. The researchers observed that the structural damage caused by the virus, combined with the lingering presence of "reprogrammed" immune cells, provided a fertile ground for cancerous cells to take root and proliferate. In mouse models, those that survived severe infections were not only more likely to develop tumors but also experienced more aggressive disease progression and higher mortality rates compared to those that had not been infected.
Analyzing the Data: Hospitalization as a Risk Marker
The laboratory findings were mirrored by a comprehensive analysis of human clinical data. By examining the medical records of thousands of patients, the UVA team identified a clear correlation between the severity of COVID-19 and the incidence of lung cancer.
The analysis revealed a 1.24-fold increase in lung cancer diagnoses among individuals who had been hospitalized due to COVID-19. Crucially, this elevated risk remained consistent even after accounting for traditional risk factors such as age, sex, and smoking history. This suggests that the viral infection itself acts as an independent "hit" to the respiratory system, potentially accelerating the oncogenic process in a manner similar to chronic chemical irritants.
Interestingly, the study noted a sharp divide based on the severity of the initial illness. While those hospitalized for severe COVID-19 faced a higher risk, patients who experienced only mild infections did not show an increased incidence of lung cancer. In some cohorts of mild cases, the researchers even observed a slight decrease in cancer rates, suggesting that a well-regulated immune response to a minor infection might actually bolster the body’s surveillance against abnormal cell growth.
The Protective Power of Immunization
One of the most vital takeaways from the UVA study is the role of vaccination in mitigating long-term oncogenic risks. The researchers found that prior vaccination largely prevented the harmful cellular changes that predispose the lungs to cancer.
Vaccines function by "training" the immune system to recognize and neutralize a pathogen before it can cause extensive tissue damage. By preventing a mild infection from escalating into a severe, systemic inflammatory event, vaccines effectively block the cascade of immune cell reprogramming that leads to a pro-tumor environment.
"The encouraging news is that vaccination largely prevents those harmful changes for cancer growth in the lung," said Dr. Sun, who serves as the co-director of UVA’s Carter Center and is a member of the Division of Infectious Diseases and International Health. "We also believe that vaccines don’t just prevent acute hospitalization after contracting the virus. They may also reduce the long-term fallout of severe infection, including the kind of immune scarring that can increase cancer risk."
Clinical Implications: A New Paradigm for Lung Cancer Screening
The discovery that severe respiratory infections can serve as a precursor to lung cancer may fundamentally change how physicians approach post-viral care. For decades, the primary trigger for lung cancer screening—typically via low-dose CT scans—has been a patient’s smoking history. The UVA study suggests that a history of severe viral pneumonia should perhaps be viewed through a similar lens.
Jeffrey Sturek, MD, PhD, a UVA physician-scientist and study collaborator, emphasized the need for a shift in monitoring protocols. "We’ve known for a long time that things like smoking increase the risk for lung cancer. The results from this study suggest that we may need to think about severe respiratory viral infection similarly," Sturek noted. "In future studies, we may want to consider a similar approach after severe respiratory viral infection, recommending close monitoring to catch cancer early when treatment is most effective."
With tens of millions of people worldwide having experienced "Long COVID" or severe pulmonary sequelae following the pandemic, the scale of the population at potential risk is significant. The researchers argue that enhanced surveillance for these individuals could lead to earlier detection, which is the single most important factor in improving lung cancer survival rates.
Chronology of the Research and Institutional Support
The study represents the culmination of several years of intensive research, beginning during the height of the COVID-19 pandemic when clinical observations first suggested that recovered patients were suffering from long-term "immune scarring."
The project was supported by the Paul and Diane Manning Institute of Biotechnology at UVA, which aims to accelerate the transition of laboratory discoveries into clinical treatments. The research also drew upon the resources of the UVA Comprehensive Cancer Center, one of only 57 centers in the United States to hold the National Cancer Institute’s "comprehensive" designation. This designation recognizes excellence in both patient care and the kind of high-impact, transdisciplinary research demonstrated in Dr. Sun’s study.
The findings were a collaborative effort involving a large team of researchers, including Wei Qian, Xiaoqin Wei, and Andrew J. Barros, among others. The project received extensive funding from the National Institutes of Health (NIH) through various grants focused on immunology, aging, and lung health, as well as support from the American Lung Association.
Broader Impact and Future Directions
The implications of this research extend beyond COVID-19 and influenza. It raises questions about the long-term effects of other respiratory pathogens and environmental factors that cause severe lung inflammation. By identifying the specific immune pathways—namely the abnormal behavior of neutrophils and macrophages—the research opens the door for the development of new "immunopreventative" therapies.
In the future, it may be possible to develop treatments that "reset" the lung’s immune environment after a severe infection, clearing out the pro-tumor cells before they can facilitate cancer growth. For now, the study serves as a powerful reminder of the importance of public health measures.
"Our goal is to help doctors identify who may be at higher risk of lung cancer after a severe infection and develop targeted ways to prevent and treat lung cancer after prior pneumonia," Dr. Sun concluded.
As the global medical community continues to grapple with the long-term consequences of the pandemic, the UVA study provides a critical roadmap. It underscores the fact that the benefits of vaccination are not merely temporary or confined to the prevention of acute illness; rather, immunization may serve as a long-term investment in oncological health, protecting the very cellular architecture of the lungs from the insidious effects of viral trauma.
